literature

HIV mutation literature information.

The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.

PMID: 21763726 2011 Antiviral research

Abstract: The following recombinant viruses were generated and tested: L33F, M46I, G48V, I54V, I84V + L90M, M46I + L90M, G48V + L90M, M46I + I54V + L90M, L33F + M46I + L90M.

Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.

PMID: 21765365 2011 Journal of acquired immune deficiency syndromes (1999)

Method: An OLA was performed on all amplicons derived from plasma and PBMC using probes that detect mutations associated with high-level drug-resistance to NFV, codons D30N (AAT) and L90M (ATG), nucleoside reverse transcriptase inhibitors (NRTI) at codons K70R (AGA), M184V (GTG), and T215F/Y (TTC, TAC), and non-nucleoside reverse transcriptase inhibitors (NNRTI) at codons K103N (AAC), Y181C (TGT), and G190A (GCA) as described.

Result: She had ART-associated suppression of viral replication, but subsequently her virus rebounded with the

PMID: 21871090 2011 Virology journal

Abstract: Only one patient, CRF02_AG, showed major resistance mutation L90M.

Result: However, only patient SE59 had the major mutation L90M (1/28; 3.5%).

Table: L90M

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

PMID: 21896904 2011 Antimicrobial agents and chemotherapy

Abstract: IVRS performed with r13025, a multiple-PI-resistant recombinant clinical isolate, and TMC310911 selected for mutations L10F, I47V, and L90M (FC in TMC310911 EC(50) = 16).

Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

PMID: 22046345 2011 PloS one

Result: Both specimens harboured mutations F53L and L90M at PR and M41L, K103N, L210W and T215D at RT.

Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

PMID: 22110581 2011 PloS one

Table: L90M

Correlation between resistance profile and immunosuppression in heavily treated HIV-1 infected Romanian patients.

PMID: 22180722 2011 Romanian biotechnological letters

Discussion: A similar pattern was displayed by isolates from our study, 50% of these harbouring the L89M polymorphism, while only 5.3% the L90M mutation.

Discussion: Regarding protease inhibitors susceptibility, in Brazilian subtype F1 isolates, presence of the L89M polymorphism in the protease gene was related to the maintenance of viral fitness, conferring a higher genetic barrier to the accumulation of the L90M resistance mutation, the latter being considered a predictor of failure to Kaletra-based regimens.

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

PMID: 22211659 2011 Current HIV research

Abstract: About 60% of tests reported L10FIRVC, M36ILV, M46IL, I54VLAMTS, V82AFTSLI, and L90M mutations in the protease region.

Antiretroviral drug resistance in HIV-infected patients in Colombia.

PMID: 19665910 2010 International journal of infectious diseases

Abstract: The most common mutations were 184V (n=48; 62.3%), 103N (n=37; 48.1%), G190A/S (n=9; 11.7%), and L90M (n=9; 11.7%).

Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.

PMID: 19915448 2010 AIDS (London, England)

Abstract: Protease inhibitor resistance rates in women receiving nelfinavir were 1.1% for D30N (1.1% by ASPCR) and 1.1% for L90M.

Result: Using population sequencing, each of the D30N and L90M mutations were detected in one out of 87 women receiving nelfinavir during PLAT (1.1% [95% CI: 0.03%-6.24%] for each mutation).

Browser Board

Co-occurred Entities

Filtrator